Protavio’s Multiplex IVD pipeline Unveiled at HUPO 2024

Protavio's booth at HUPO 2024

Protavio is excited to share the highlights of our impactful presence at the HUPO 2024 World Congress, held from October 20th to 24th in the beautiful city of Dresden, Germany. The event was a convergence of innovation and expertise, bringing together the brightest minds in proteomics from around the globe. It served as an exceptional platform for us to connect with leading researchers, industry experts, and fellow innovators who are shaping the future of proteomics.

At HUPO 2024, we had the opportunity to unveil the latest affinity proteomics technologies to the global proteomics community. During the congress, we showcased our pipeline for multiplex in vitro diagnostics (IVD) through the example of the DIOPTRA project, which aims to develop a groundbreaking diagnostic tool for the early detection of colorectal cancer (CRC). By showing how our cutting-edge Olink and Luminex solutions are being applied in this project, we demonstrated how these technologies can transform research methodologies. Our platforms empower researchers to delve deeper into proteomic studies, enabling the simultaneous analysis of multiple biomarkers with high sensitivity and specificity, thereby accelerating scientific discoveries.

The DIOPTRA project represents a significant stride in the fight against CRC, one of the most common and lethal cancers worldwide. By leveraging our advanced affinity proteomics technologies, we aim to facilitate earlier detection, improve patient outcomes, and reduce healthcare costs associated with late-stage diagnosis. We highlighted the potential of multiplex IVD to revolutionize diagnostics, and the role Protavio is playing in making this a reality.

Engaging with the global proteomics community at HUPO 2024 was truly inspiring. We participated in insightful discussions on emerging trends, shared best practices, and explored collaborative opportunities with academic institutions, research organizations, and industry leaders. The enthusiastic response to the DIOPTRA project reaffirmed our commitment to pushing the boundaries of proteomics research and its applications in diagnostics. 

In addition to showcasing the technologies we use, we attended a variety of sessions that covered the latest advancements in proteomics, from novel analytical techniques to computational biology and data analysis. These sessions enriched our understanding of the challenges and opportunities within the field, and have sparked new ideas for future projects.

We extend our sincere gratitude to the HUPO 2024 organizers for orchestrating such a remarkable event, and to all the  attendees who visited our booth and engaged with us. Your enthusiasm and insights are the fuel that drives our passion for innovation.

This is an exciting time for Protavio, and we invite you to join us on this journey. Stay tuned for upcoming announcements and opportunities to collaborate.

Scroll to Top